XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rate) disease indications. Co.'s three primary product candidates are: XRx-008, a program for the treatment of autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury associated with severe virus infection and associated health consequences; and XRx-225, a program for the treatment of type 2 diabetic nephropathy. We show 3 historical shares outstanding datapoints in our XRTX shares outstanding history coverage, used to compute XRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing XRTX market cap history over the course of time is important for investors
interested in comparing XRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of XRTX versus a peer is one thing; comparing
XRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like XRTX can fluctuate over the course of history.
With this page we aim to empower investors researching XRTX by allowing them to research the XRTX market cap history. |
Free XRTX Email Alerts:
Video: The Importance of Market Cap
